Moderna, Inc. $MRNA Stock Holdings Raised by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 3.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 65,750 shares of the company’s stock after buying an additional 2,400 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Moderna were worth $12,661,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Physician Wealth Advisors Inc. increased its holdings in Moderna by 8.3% during the third quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company’s stock worth $171,000 after buying an additional 68 shares during the last quarter. Fortitude Family Office LLC raised its position in Moderna by 53.1% during the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after acquiring an additional 77 shares in the last quarter. TD Waterhouse Canada Inc. lifted its stake in Moderna by 2.6% in the second quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock valued at $246,000 after acquiring an additional 85 shares during the last quarter. SteelPeak Wealth LLC lifted its stake in Moderna by 3.9% in the third quarter. SteelPeak Wealth LLC now owns 3,397 shares of the company’s stock valued at $654,000 after acquiring an additional 127 shares during the last quarter. Finally, Western Pacific Wealth Management LP acquired a new stake in Moderna in the third quarter valued at $29,000. 75.33% of the stock is owned by institutional investors.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized cancer-vaccine candidate remains a key potential catalyst. Recent clinical data have encouraged investors, and Chief Executive Stéphane Bancel defended the melanoma results, saying the data could improve over time and that competitors may not easily replicate the company’s technology. Will Moderna Soar on Nov. 6? Moderna’s CEO discusses its cancer vaccine
• Positive Sentiment: Coverage comparing Moderna with BioNTech highlights the company’s oncology platform and its potential role in the growing mRNA cancer-vaccine market. Successful follow-up data could support Moderna’s long-term growth narrative. Moderna cancer results versus BioNTech
• Neutral Sentiment: Investor attention is elevated ahead of Moderna’s quarterly earnings release. The report may provide updated financial guidance and more information about the company’s pipeline, but heavy searches alone do not change the underlying outlook. Moderna projected to announce quarterly earnings
• Negative Sentiment: Analysts expect Moderna’s third-quarter earnings to decline, and Zacks says the company lacks the combination of factors typically associated with a likely earnings beat. That is weighing on expectations ahead of the report. Moderna Q3 earnings preview
• Negative Sentiment: William Blair lowered Moderna to Market Perform, while an analyst also reduced the company’s fiscal 2028 EPS estimate. The actions reinforce concerns about the premium valuation, limited near-term earnings visibility and the time required for oncology programs to mature. Moderna rating lowered to Market Perform Moderna FY2028 EPS estimate lowered

Insider Activity at Moderna

In other news, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider directly owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $220.72, for a total value of $8,640,084.40. Following the sale, the president owned 1,636,565 shares of the company’s stock, valued at approximately $361,222,626.80. The trade was a 2.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 197,251 shares of company stock worth $33,875,904 over the last ninety days. Insiders own 10.80% of the company’s stock.

Moderna Trading Down 0.5%

MRNA opened at $221.72 on Friday. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $254.48. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The firm has a market capitalization of $88.52 billion, a price-to-earnings ratio of -27.75 and a beta of 1.09. The company’s 50 day moving average price is $182.49 and its two-hundred day moving average price is $86.52.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. The business had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. Moderna’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period last year, the company earned ($2.13) EPS. As a group, research analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on MRNA shares. Loop Capital set a $135.00 target price on shares of Moderna in a research note on Wednesday, August 19th. Barclays boosted their price target on Moderna from $48.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Monday, August 24th. Sanford C. Bernstein restated a “market perform” rating on shares of Moderna in a research note on Friday, September 25th. JPMorgan Chase & Co. raised their price objective on Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $230.00 price objective (up from $167.00) on shares of Moderna in a research report on Monday, October 26th. Six equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and an average price target of $107.10.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.